Recombinant factor VIIa in trauma patients without coagulation disorders.

Corey Scher, Venod Narine, Daniel Chien

Journal: Anesthesiology clinics 2011;28(4):681-90

PMID: 21074745

Full Text on Elsevier Science View on PubMed

Abstract

Recombinant activated factor VIIa (rFVIIa) has many clinical applications for patients with congenital bleeding disorders and in a variety of clinical settings. Additional studies in the future are ongoing and should provide the clinical anesthesiologist an additional option during certain bleeding states. Specific recommendations as to timing of administration and frequent monitoring of ionized calcium status are suggested at this time. Optimization of fibrinogen levels, platelet levels, pH, and body temperature will enhance efficacy of rFVIIa.

Address: Department of Anesthesiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467-2490, USA. [email protected]

DOI: 10.1016/j.anclin.2010.08.011

Link outs

Free resources

Medical:

https://medlineplus.gov/woundsandinjuries.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Cerebral Hemorrhage, Factor VIIa, Hemophilia A, Hemophilia B, Humans, Postpartum Hemorrhage, Recombinant Proteins, Thromboplastin, Warfare, Wounds and Injuries